17 completed, 12 recruiting, 8 active not recruiting, 3 withdrawn. 25 Phase 2, 24 Phase 1, 3 Phase 3.
Follow enasidenib: new trials by email Literature Review of enasidenib trials Research Report on enasidenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Myelodysplastic Syndrome | Phase 2 | Recruiting | National Cancer Institute (NCI) | 54 | 2025-06-12 | 2026-10-22 |
| Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 93 | 2025-05-16 | 2026-10-13 |
| A Study of Enasidenib in People With T-Cell Lymphoma Enasidenib, Rituximab - T-cell Lymphoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 2 | 2024-12-24 | 2026-08-20 |
| Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial Enasidenib - Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance | Phase 2 | Recruiting | Washington University School of Medicine | 15 | 2024-10-10 | 2026-08-10 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-10-23 |
| Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors Enasidenib - Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 40 | 2024-03-04 | 2026-10-16 |
| A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) Gilteritinib, Ivosidenib, Enasidenib - Acute Myeloid Leukemia (AML) | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 8 | 2023-10-25 | 2026-10-15 |
| Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 1 | 2023-08-14 | 2026-01-09 |
| Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Cobimetinib, Enasidenib Mesylate - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Completed | City of Hope Medical Center | 3 | 2023-04-28 | 2026-05-05 |
| IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) Azacitidine, Biopsy, Enasidenib - Acute Myeloid Leukemia | Phase 2 | Recruiting | Alice Mims | 125 | 2022-09-13 | 2026-06-23 |
| Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation Bosutinib Monohydrate, Decitabine, Enasidenib Mesylate - Recurrent Acute Myeloid Leukemia | Phase 1 | Withdrawn | City of Hope Medical Center | 2022-06-25 | 2022-06-09 | |
| Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation Enasidenib mesylat dose escalation - Leukemia, Leukemia, Myeloid | Phase 1 / Phase 2 | Completed | Tian Yi Zhang | 17 | 2022-01-12 | 2026-09-03 |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms Ivosidenib, Enasidenib, Fedratinib - IDH Mutation, IDH1 Mutation | Phase 1 | Withdrawn | University of Chicago | 2021-10-29 | 2024-07-31 | |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission Decitabine and Cedazuridine, Enasidenib, Gilteritinib - Acute Myeloid Leukemia | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 125 | 2021-10-25 | 2026-10-09 |
| A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance Enasidenib - Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 4 | 2021-10-06 | 2026-01-27 |
| Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Decitabine and Cedazuridine, Enasidenib, Ivosidenib - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 84 | 2021-05-24 | 2026-05-20 |
| Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation Ruxolitinib, Enasidenib - Accelerated/Blast-phase Myeloproliferative Neoplasm, Chronic-phase Myelofibrosis | Phase 2 | Completed | John Mascarenhas | 6 | 2021-01-14 | 2025-02-04 |
| Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment Enasidenib - Hepatic Impairment | Phase 1 | Completed | Celgene | 40 | 2020-11-13 | 2024-07-15 |
| Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Enasidenib, Venetoclax - Acute Myeloid Leukemia, Relapsed Cancer | Phase 1 / Phase 2 | Terminated | University Health Network, Toronto | 27 | 2020-11-05 | 2024-01-24 |
| IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT Enasidenib - Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 2 | Completed | Heinrich-Heine University, Duesseldorf | 50 | 2020-08-27 | 2024-09-19 |
Showing 20 of 44. Sign in to see all of them.
Leukemia, Myeloid, Acute (26) · Myelodysplastic Syndromes (7) · Leukemia, Myelomonocytic, Chronic (5) · Leukemia (4) · Hematologic Neoplasms (3) · Myeloproliferative Disorders (3) · Chondrosarcoma (2) · Leukemia, Myeloid (2) · Multiple Myeloma (2) · Neoplasms (2) · Primary Myelofibrosis (2) · Anemia (1) · Anemia, Refractory, with Excess of Blasts (1) · Blast Crisis (1) · Breast Neoplasms (1)
Celgene (11) · M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (4) · City of Hope Medical Center (3) · Memorial Sloan Kettering Cancer Center (3) · Alice Mims (1) · Beat AML, LLC (1) · Children's Oncology Group (1) · Groupe Francophone des Myelodysplasies (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Heinrich-Heine University, Duesseldorf (1) · Institut de Recherches Internationales Servier (1) · Jazz Pharmaceuticals (1) · John Mascarenhas (1) · Jonsson Comprehensive Cancer Center (1)
United States (37) · France (7) · Canada (6) · Germany (5) · Australia (4) · Netherlands (4) · Spain (4) · Belgium (3) · Italy (3) · Puerto Rico (3) · South Korea (3) · United Kingdom (3) · Austria (2) · Denmark (2) · Sweden (2)
Courtney DiNardo (2) · Edward O'Mara, MD (2) · Eytan Stein, MD (2) · Leon Carayannopoulos, MD (2) · Alice Mims, MD (1) · Alice S Mims, MD (1) · Amandeep Salhotra (1) · Anand A Patel (1) · B.J. Wouters (1) · Birgit Geoerger, MD (1) · Brian Ball (1) · Caspian Oliai, MD (1) · Charalampos Floudas, M.D. (1)
PMID 38507688, PMID 33394722, PMID 29243965, PMID 29950729, PMID 31538815, PMID 32145771, PMID 32700065, PMID 33119479, PMID 33892407, PMID 34347542, PMID 34427990, PMID 34543871, PMID 34672961, PMID 35078972, PMID 35166065, PMID 35292802, PMID 35973199, PMID 36150050, PMID 36902217, PMID 38010220, PMID 39863139, PMID 40073835, PMID 40504618, PMID 40513054, PMID 40557912, PMID 40932876, PMID 41075807, PMID 41838385, PMID 42686334
2015 (2), P30CA033572 (2), U10CA180888 (2), 2014 (1), 2016 (1), 2018 (1), 2019 (1), P01CA108671 (1), P30CA016672 (1), R01CA262496 (1), U10CA180821 (1), U10CA180886 (1)